HRP20100265T1 - Smjesa od pirimidilaminobenzamid spojeva i imatiniba za liječenje ili prevenciju proliferativnih bolesti - Google Patents

Smjesa od pirimidilaminobenzamid spojeva i imatiniba za liječenje ili prevenciju proliferativnih bolesti Download PDF

Info

Publication number
HRP20100265T1
HRP20100265T1 HR20100265T HRP20100265T HRP20100265T1 HR P20100265 T1 HRP20100265 T1 HR P20100265T1 HR 20100265 T HR20100265 T HR 20100265T HR P20100265 T HRP20100265 T HR P20100265T HR P20100265 T1 HRP20100265 T1 HR P20100265T1
Authority
HR
Croatia
Prior art keywords
imatinib
mixture
treatment
prevention
proliferative diseases
Prior art date
Application number
HR20100265T
Other languages
English (en)
Croatian (hr)
Inventor
Alland Leila
W. Manley Paul
Mestan Juergen
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of HRP20100265T1 publication Critical patent/HRP20100265T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
HR20100265T 2005-06-03 2006-06-02 Smjesa od pirimidilaminobenzamid spojeva i imatiniba za liječenje ili prevenciju proliferativnih bolesti HRP20100265T1 (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US68775805P 2005-06-03 2005-06-03
PCT/US2006/021307 WO2006132930A1 (en) 2005-06-03 2006-06-02 Combination of pyrimidylaminobenzamide compounds and imatinib for treating or preventing proliferative diseases

Publications (1)

Publication Number Publication Date
HRP20100265T1 true HRP20100265T1 (hr) 2010-06-30

Family

ID=36968749

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20100265T HRP20100265T1 (hr) 2005-06-03 2006-06-02 Smjesa od pirimidilaminobenzamid spojeva i imatiniba za liječenje ili prevenciju proliferativnih bolesti

Country Status (26)

Country Link
US (2) US7767688B2 (cg-RX-API-DMAC10.html)
EP (1) EP1893213B1 (cg-RX-API-DMAC10.html)
JP (2) JP5281887B2 (cg-RX-API-DMAC10.html)
KR (1) KR101276425B1 (cg-RX-API-DMAC10.html)
CN (1) CN101180060B (cg-RX-API-DMAC10.html)
AT (1) ATE457727T1 (cg-RX-API-DMAC10.html)
AU (1) AU2006255559B2 (cg-RX-API-DMAC10.html)
BR (1) BRPI0611506A2 (cg-RX-API-DMAC10.html)
CA (1) CA2608814C (cg-RX-API-DMAC10.html)
CY (1) CY1110027T1 (cg-RX-API-DMAC10.html)
DE (1) DE602006012313D1 (cg-RX-API-DMAC10.html)
DK (1) DK1893213T3 (cg-RX-API-DMAC10.html)
ES (1) ES2339593T3 (cg-RX-API-DMAC10.html)
HR (1) HRP20100265T1 (cg-RX-API-DMAC10.html)
IL (1) IL187408A0 (cg-RX-API-DMAC10.html)
MA (1) MA29565B1 (cg-RX-API-DMAC10.html)
MX (1) MX2007015159A (cg-RX-API-DMAC10.html)
NO (1) NO20080037L (cg-RX-API-DMAC10.html)
NZ (1) NZ563446A (cg-RX-API-DMAC10.html)
PL (1) PL1893213T3 (cg-RX-API-DMAC10.html)
PT (1) PT1893213E (cg-RX-API-DMAC10.html)
RU (1) RU2430727C2 (cg-RX-API-DMAC10.html)
SI (1) SI1893213T1 (cg-RX-API-DMAC10.html)
TN (1) TNSN07453A1 (cg-RX-API-DMAC10.html)
WO (1) WO2006132930A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA200709473B (cg-RX-API-DMAC10.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1893213T3 (da) * 2005-06-03 2010-06-07 Novartis Ag Kombination af pyrimidylaminobenzamidforbindelser og imatinib til behandling eller forebyggelse af proliferative sygdomme
TW201102068A (en) * 2009-06-02 2011-01-16 Novartis Ag Treatment of ophthalmologic disorders mediated by alpha-carbonic anhydrase isoforms
EP2382976A1 (en) * 2010-04-30 2011-11-02 Hiroshima University Use of pdgf-r inhibitors for the treatment of lymph node metastasis of gastric cancer
CN102719530B (zh) * 2012-05-07 2013-11-06 厦门艾德生物医药科技有限公司 一种用于检测PDGFRα基因突变的引物、探针及试剂盒
KR101386697B1 (ko) 2012-06-18 2014-04-18 아주대학교산학협력단 이매티닙 또는 이의 약학적으로 허용되는 염을 유효성분으로 포함하는 혈관 투과성 관련 질환의 치료 또는 예방용 조성물
EP3658190B1 (en) 2017-07-26 2025-10-01 Oncosol Limited Liquid dosage forms of imatinib
TWI787523B (zh) 2018-06-15 2022-12-21 漢達生技醫藥股份有限公司 達沙替尼十二烷基硫酸鹽之結晶

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CO4940418A1 (es) * 1997-07-18 2000-07-24 Novartis Ag Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso
GB0215676D0 (en) * 2002-07-05 2002-08-14 Novartis Ag Organic compounds
AR042042A1 (es) * 2002-11-15 2005-06-08 Sugen Inc Administracion combinada de una indolinona con un agente quimioterapeutico para trastornos de proliferacion celular
DK1893213T3 (da) * 2005-06-03 2010-06-07 Novartis Ag Kombination af pyrimidylaminobenzamidforbindelser og imatinib til behandling eller forebyggelse af proliferative sygdomme

Also Published As

Publication number Publication date
SI1893213T1 (sl) 2010-05-31
CA2608814C (en) 2013-09-03
DK1893213T3 (da) 2010-06-07
KR20080021633A (ko) 2008-03-07
NZ563446A (en) 2011-02-25
PL1893213T3 (pl) 2010-08-31
US20100190800A1 (en) 2010-07-29
RU2430727C2 (ru) 2011-10-10
US8653093B2 (en) 2014-02-18
BRPI0611506A2 (pt) 2010-09-14
CN101180060A (zh) 2008-05-14
JP5281887B2 (ja) 2013-09-04
PT1893213E (pt) 2010-04-19
ES2339593T3 (es) 2010-05-21
US7767688B2 (en) 2010-08-03
KR101276425B1 (ko) 2013-06-19
CY1110027T1 (el) 2015-01-14
IL187408A0 (en) 2011-07-31
US20080312252A1 (en) 2008-12-18
WO2006132930A1 (en) 2006-12-14
RU2007147957A (ru) 2009-07-20
JP2008542390A (ja) 2008-11-27
HK1115528A1 (en) 2008-12-05
AU2006255559A1 (en) 2006-12-14
EP1893213A1 (en) 2008-03-05
MA29565B1 (fr) 2008-06-02
CA2608814A1 (en) 2006-12-14
JP2013035853A (ja) 2013-02-21
AU2006255559B2 (en) 2009-12-17
ATE457727T1 (de) 2010-03-15
CN101180060B (zh) 2011-12-28
EP1893213B1 (en) 2010-02-17
NO20080037L (no) 2008-01-03
DE602006012313D1 (de) 2010-04-01
ZA200709473B (en) 2008-12-31
MX2007015159A (es) 2008-02-15
TNSN07453A1 (en) 2009-03-17

Similar Documents

Publication Publication Date Title
PE20120626A1 (es) Composiciones farmaceuticas que comprende nilotinib
BRPI0114870B8 (pt) uso de 4-(4-metilpiperazin-1-ilmetil)-n-[4-metil-3-(4-piridin-3-il)pirimidin-2-amino)fenil]-benzamida para a fabricação de composições farmacêuticas para tratamento de tumores estromais gastrointestinais
JP2009532438A5 (cg-RX-API-DMAC10.html)
JP2018502877A5 (cg-RX-API-DMAC10.html)
BR112013032122A2 (pt) liberação modificada de 4-metil-3-[[4-(3-piridinil)-2-pirimidinil]amino]-n-[5-(4-metil-1h-imidazol-1-il)-3-(trifluorometil)fenil] benzamida solubilizada usando ácidos orgânicos
RU2003114752A (ru) Лечение желудочно-кишечных стромальных опухолей
JP2017504611A5 (cg-RX-API-DMAC10.html)
PE20090617A1 (es) Compuestos amino-5-[-4-(difluorometoxi)fenil]-5-fenilimidazolona para la inhibicion de -secretasa
NZ590839A (en) Treatment of pulmonary arterial hypertension
RU2008143703A (ru) ПРИМЕНЕНИЕ ИНГИБИТОРОВ c-Src В КОМБИНАЦИИ С ПИРИМИДИЛАМИНОБЕНЗАМИДОМ ДЛЯ ЛЕЧЕНИЯ ЛЕЙКОЗА
NZ590177A (en) Use of pyrimidylaminobenzamide derivatives for the treatment of fibrosis
PH12019502830A1 (en) Pharmaceutical formulations of n-(2-(2-(dimethylamino)ethoxy)-4-methoxy-5-((4-(1-methyl-1h-indol-3-yl)pyrimidin-2-yl)amino)phenyl)acrylamide and salts thereof
JP2016020375A5 (cg-RX-API-DMAC10.html)
MA35636B1 (fr) Formulation à libération immédiate de 4-méthyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-n-[5-(4-méthyl- 1h-imidazol-1-yl)-3-(trifluorométhyl)phényl]benzamide
JP2012528824A5 (cg-RX-API-DMAC10.html)
JP2009537606A5 (cg-RX-API-DMAC10.html)
RU2007147957A (ru) Комбинация производных пиримидиламинобензамида и иматиниба для лечения или профилактики пролиферативных заболеваний
RU2008143704A (ru) КОМБИНАЦИЯ, ВКЛЮЧАЮЩАЯ А) ПИРИМИДИЛАМИНОБЕНЗАМИД И Б) ИНГИБИТОР КИНАЗЫ Thr315lle
JP2008542390A5 (cg-RX-API-DMAC10.html)
ES2421587T3 (es) Uso de derivados de pirimidilaminobenzamida para el tratamiento de mastocitosis sistémica
NZ597864A (en) Methods and compositions for treating leukemia
RU2008105832A (ru) Органические соединения
JP2012519668A5 (cg-RX-API-DMAC10.html)
ATE489109T1 (de) Behandlung von gastrointestinalen stromatumoren mit imatinib und midostaurin
RU2011140404A (ru) Применение производных пиримидиламинобензамида для лечения нарушений, опосредованных киназой, содержащей мотив лейциновой "молнии" и стерильный альфа мотив (zak)